Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?

doi:10.1513/pats.200703-038BR

Review

. 2007 Aug 1;4(4):367-9.

doi: 10.1513/pats.200703-038BR.

Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?

Bonnie W Ramsey¹

Affiliations

PMID: 17652503
PMCID: PMC2647601
DOI: 10.1513/pats.200703-038BR

Review

Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?

Bonnie W Ramsey. Proc Am Thorac Soc. 2007.

. 2007 Aug 1;4(4):367-9.

doi: 10.1513/pats.200703-038BR.

Author

Bonnie W Ramsey¹

Affiliation

¹ Department of Pediatrics, University of Washington, Seattle, WA 98105-0371, USA. bonnie.ramsey@seattlechildrens.org

PMID: 17652503
PMCID: PMC2647601
DOI: 10.1513/pats.200703-038BR

No abstract available

PubMed Disclaimer

Cited by

Update in cystic fibrosis 2007.
Accurso FJ. Accurso FJ. Am J Respir Crit Care Med. 2008 May 15;177(10):1058-61. doi: 10.1164/rccm.200801-069UP. Am J Respir Crit Care Med. 2008. PMID: 18460460 Free PMC article. Review. No abstract available.
Potential role of high-mobility group box 1 in cystic fibrosis airway disease.
Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, McQuaid DB, Noerager BD, Gaggar A, Clancy JP, O'Neal W, Sorscher EJ, Abraham E, Blalock JE. Rowe SM, et al. Am J Respir Crit Care Med. 2008 Oct 15;178(8):822-31. doi: 10.1164/rccm.200712-1894OC. Epub 2008 Jul 24. Am J Respir Crit Care Med. 2008. PMID: 18658107 Free PMC article.
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.
Zemanick ET, Harris JK, Conway S, Konstan MW, Marshall B, Quittner AL, Retsch-Bogart G, Saiman L, Accurso FJ. Zemanick ET, et al. J Cyst Fibros. 2010 Jan;9(1):1-16. doi: 10.1016/j.jcf.2009.09.003. Epub 2009 Oct 14. J Cyst Fibros. 2010. PMID: 19833563 Free PMC article. Review.
In vivo readout of CFTR function: ratiometric measurement of CFTR-dependent secretion by individual, identifiable human sweat glands.
Wine JJ, Char JE, Chen J, Cho HJ, Dunn C, Frisbee E, Joo NS, Milla C, Modlin SE, Park IH, Thomas EA, Tran KV, Verma R, Wolfe MH. Wine JJ, et al. PLoS One. 2013 Oct 24;8(10):e77114. doi: 10.1371/journal.pone.0077114. eCollection 2013. PLoS One. 2013. PMID: 24204751 Free PMC article.
Pediatric hospital medicine and children with medical complexity: past, present, and future.
Simon TD, Mahant S, Cohen E. Simon TD, et al. Curr Probl Pediatr Adolesc Health Care. 2012 May;42(5):113-9. doi: 10.1016/j.cppeds.2012.01.002. Curr Probl Pediatr Adolesc Health Care. 2012. PMID: 22483081 Free PMC article. Review.

See all "Cited by" articles

References

1. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918–951. - PubMed
1. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637–642. - PubMed
1. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23–30. - PubMed
1. Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006;41:656–665. - PubMed
1. Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, et al. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 2005;39:339–348. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

MO1-RR00037/RR/NCRR NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Medical
- Genetic Alliance
- MedlinePlus Health Information

[1] Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918–951. - PubMed

[2] Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918–951. - PubMed

[3] Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637–642. - PubMed

[4] Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637–642. - PubMed

[5] Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23–30. - PubMed

[6] Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23–30. - PubMed

[7] Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006;41:656–665. - PubMed

[8] Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006;41:656–665. - PubMed

[9] Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, et al. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 2005;39:339–348. - PubMed

[10] Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, et al. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 2005;39:339–348. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?

Affiliation

Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?

Author

Affiliation

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical